Search results
Lupin loses appeal in EU court, will have to pay €40 mn fine in Perindopril case - CNBC TV18
CNBC TV18· 5 days agoThe European Court of Justice has upheld the European Commission’s decision to impose a fine of 40...
PLI scheme to make obesity, diabetes drugs GLP-1 coming in 2026
CNBC Awaaz· 5 days agoGlucagon-like peptide-1 (GLP-1) are a category of drugs used in the treatment of type 2 diabetes and...
Lupin shares gain 1.77% as Sensex rises
The Economic Times· 5 days agoA total of 34,891 shares changed hands on the counter till 10:35AM (IST)
Stock market update: Nifty Pharma index advances 1.37% in an upbeat market
The Economic Times· 5 days agoThe Nifty Pharma index was trading 1.37 per cent up at 19782.05.
Apple TV+ French Drama ‘A L’ombre Des Forêts’: All you may want to know about plot, cast and crew
The Economic Times· 6 days agoApple TV+ announces a new French original series, 'A L’ombre Des Forêts', starring Benoît Magimel...
Trade Setup for June 28: Nifty set for best month of 2024 after conquering 24,000 - CNBC TV18
CNBC TV18· 6 days agoThe Nifty is up nearly 7% in the month of June, which will be the best month for the index since...
EU top court rejects Servier appeal against EU antitrust fine - ET LegalWorld
The Economic Times· 6 days agoEurope's top court on Thursday rejected French drugmaker Servier's appeal against a finding by EU antitrust regulators a decade ago that its pay-for-delay deals with generic rivals were anti-competitive.
Pharma industry body mulling policy framework to guide cos on cybercrime
Business Standard India· 6 days agoThere is a need for pharmaceutical companies to have a policy framework within the Indian...
USFDA gives nod to Lupin’s generic formulation to treat eye condition
Financial Express· 6 days agoOlopatadine Hydrochloride Ophthalmic Solution USP (RLD Pataday) had an estimated annual sale of USD...
Drugmaker Servier loses EU court fight over pay-for-delay deals - ET HealthWorld | Pharma
The Economic Times· 6 days agoBlood Pressure Medicine: "The Court dismisses the appeals of Lupin, Niche Generics, Unichem...